MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
OPKO Health Cost of Revenue 2011-2026 | OPK
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 495 M | 545 M | 716 M | - | - | - | - | - | 564 M | 193 M | 48 M | 48.9 M | 27.9 M | 17.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 716 M | 17.2 M | 295 M |
Quarterly Cost of Revenue OPKO Health
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 107 M | 107 M | - | 131 M | 132 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.4 M | 10.3 M | - | 11.1 M | 12.6 M | 12.4 M | - | 12 M | 13.1 M | 11.8 M | - | 7.49 M | 6.55 M | 4.99 M | - | 4.02 M | 4.89 M | 4.18 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 132 M | 4.02 M | 33.7 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
6.6 M | $ 22.96 | -0.56 % | $ 99.4 M |  Israel |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Danaher Corporation
DHR
|
9.67 B | $ 237.64 | 1.12 % | $ 174 B | USA |
 |
DarioHealth Corp.
DRIO
|
14.4 M | $ 12.15 | -5.81 % | $ 345 M | Israel |
 |
Burning Rock Biotech Limited
BNR
|
144 M | $ 23.25 | -0.66 % | $ 250 M |  China |
 |
DexCom
DXCM
|
1.33 B | $ 66.95 | -2.16 % | $ 25.8 B | USA |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
30.4 M | $ 1.59 | -0.94 % | $ 2.02 M | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
4.18 M | $ 6.12 | - | $ 180 M | USA |
 |
IQVIA Holdings
IQV
|
10 B | $ 243.33 | 0.06 % | $ 44.1 B | USA |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 39.59 | -0.76 % | $ 1.1 B | USA |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | China |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
Natera
NTRA
|
158 M | $ 234.65 | -2.05 % | $ 23.1 B | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 17.02 | -1.16 % | $ 915 M | USA |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Pacific Biosciences of California
PACB
|
148 M | $ 1.95 | -4.66 % | $ 495 M | USA |
 |
Exact Sciences Corporation
EXAS
|
221 M | $ 102.13 | 0.34 % | $ 18.9 B | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 27.84 | -0.2 % | $ 842 M | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | $ 48.32 | -0.27 % | $ 10.8 B |  Niderland |
 |
RadNet
RDNT
|
1 B | $ 77.42 | -1.22 % | $ 5.65 B | USA |
 |
Aspira Women's Health
AWH
|
3.86 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
1.51 B | $ 141.01 | -3.31 % | $ 22.4 B | USA |
 |
Trinity Biotech plc
TRIB
|
54.9 M | $ 0.73 | -1.13 % | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
186 M | $ 35.58 | 2.42 % | $ 2.13 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
6.63 B | $ 175.1 | -1.49 % | $ 19.4 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.38 B | $ 252.61 | -0.81 % | $ 21.2 B | USA |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 183.13 | -2.7 % | $ 15.1 B | Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.52 B | $ 715.47 | 0.43 % | $ 59 B | USA |
 |
Lantheus Holdings
LNTH
|
546 M | $ 67.98 | 0.19 % | $ 4.7 B | USA |
 |
Agilent Technologies
A
|
2.91 B | $ 148.92 | 2.17 % | $ 45.3 B | USA |
 |
Biomerica
BMRA
|
4.81 M | $ 2.75 | -4.84 % | $ 6.32 M | USA |
 |
Bioventus
BVS
|
184 M | $ 8.02 | 0.25 % | $ 502 M | USA |